◎ Sugi Atlas

Atlas / Gene / NT5DC2

NT5DC2

gene
On this page

Also known as FLJ12442

Summary

NT5DC2 (5’-nucleotidase domain containing 2, HGNC:25717) is a protein-coding gene on chromosome 3p21.1, encoding 5’-nucleotidase domain-containing protein 2 (Q9H857). Promotes dephosphorylation of tyrosine 3-monooxygenase TH which decreases TH catalytic activity and leads to reduced synthesis of catecholamines including dopamine, noradrenaline and adrenaline.

Predicted to enable 5’-nucleotidase activity. Predicted to be involved in negative regulation of dopamine biosynthetic process; negative regulation of oxidoreductase activity; and negative regulation of peptidyl-serine phosphorylation. Located in mitochondrion.

Source: NCBI Gene 64943 — RefSeq curated summary.

At a glance

  • GWAS associations: 35
  • Clinical variants (ClinVar): 124 total
  • Druggable target: yes
  • MANE Select transcript: NM_001134231

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:25717
Approved symbolNT5DC2
Name5’-nucleotidase domain containing 2
Location3p21.1
Locus typegene with protein product
StatusApproved
AliasesFLJ12442
Ensembl geneENSG00000168268
Ensembl biotypeprotein_coding
OMIM621077
Entrez64943

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 16 protein_coding, 6 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000307076, ENST00000422318, ENST00000459839, ENST00000462261, ENST00000463947, ENST00000466112, ENST00000469616, ENST00000471522, ENST00000478091, ENST00000479024, ENST00000486792, ENST00000487779, ENST00000489316, ENST00000490681, ENST00000492555, ENST00000900516, ENST00000900517, ENST00000919385, ENST00000919386, ENST00000919387, ENST00000919388, ENST00000919389, ENST00000919390, ENST00000919391, ENST00000965313

RefSeq mRNA: 2 — MANE Select: NM_001134231 NM_001134231, NM_022908

CCDS: CCDS2858, CCDS46843

Canonical transcript exons

ENST00000422318 — 14 exons

ExonStartEnd
ENSE000018596945252438752524731
ENSE000034640655252801352528073
ENSE000035305125252886152528935
ENSE000035370535252481752524881
ENSE000035557165252761752527718
ENSE000036226515252844652528539
ENSE000036266745252520952525295
ENSE000036327845252782952527931
ENSE000036435555252818352528311
ENSE000036599065252496352525103
ENSE000036666205252915052529334
ENSE000036860215252863752528692
ENSE000037856435252729452527375
ENSE000038471185253350652533857

Expression profiles

Bgee: expression breadth ubiquitous, 228 present calls, max score 99.00.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.1413 / max 133.2881, expressed in 1690 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter IDTPM avgSamples expressed
4244713.33331650
424453.96311210
424492.5863882
424421.4336795
424461.0443587
424440.7395396
424410.3468182
424390.2490105
424380.215096
424480.150258

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
ganglionic eminenceUBERON:000402399.00gold quality
ventricular zoneUBERON:000305398.99gold quality
stromal cell of endometriumCL:000225598.76gold quality
embryoUBERON:000092297.92gold quality
apex of heartUBERON:000209897.74gold quality
right coronary arteryUBERON:000162597.57gold quality
cortical plateUBERON:000534397.57gold quality
right atrium auricular regionUBERON:000663197.46gold quality
left coronary arteryUBERON:000162697.23gold quality
lower esophagus mucosaUBERON:003583497.20gold quality
right hemisphere of cerebellumUBERON:001489096.37gold quality
endocervixUBERON:000045896.33gold quality
adenohypophysisUBERON:000219696.29gold quality
coronary arteryUBERON:000162196.26gold quality
right testisUBERON:000453496.14gold quality
cerebellar hemisphereUBERON:000224596.08gold quality
tibial nerveUBERON:000132396.05gold quality
cerebellar cortexUBERON:000212995.95gold quality
left testisUBERON:000453395.93gold quality
right adrenal glandUBERON:000123395.80gold quality
cardiac atriumUBERON:000208195.80gold quality
left adrenal glandUBERON:000123495.62gold quality
left adrenal gland cortexUBERON:003582595.61gold quality
left ovaryUBERON:000211995.59gold quality
ectocervixUBERON:001224995.51gold quality
esophagus mucosaUBERON:000246995.28gold quality
right ovaryUBERON:000211895.16gold quality
skin of legUBERON:000151195.01gold quality
right adrenal gland cortexUBERON:003582795.00gold quality
pituitary glandUBERON:000000794.91gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

ExperimentMarker?Max mean expression
E-HCAD-13yes25.03
E-MTAB-9689no423.89
E-ANND-3no0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

5 targeting NT5DC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-674599.7465.331321
HSA-MIR-6776-5P98.5467.431304
HSA-MIR-1255B-2-3P97.8067.04880
HSA-MIR-428897.1167.231636
HSA-MIR-123195.1065.63663

Literature-anchored findings (GeneRIF, showing 7)

  • Disruption of NT5DC2 in GSCs markedly reduces the expression of Fyn, a Src family proto-oncogene that has been implicated in the regulation of GBM progression. The expression of NT5DC2 strongly correlated with increased aggression of human gliomas, but not that of other brain tumors. (PMID:30978441)
  • NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma. (PMID:32382041)
  • NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling. (PMID:32962856)
  • NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: A mechanism involving VEGF signaling. (PMID:32991874)
  • Decreased RNAbinding protein IGF2BP2 downregulates NT5DC2, which suppresses cell proliferation, and induces cell cycle arrest and apoptosis in diffuse large Bcell lymphoma cells by regulating the p53 signaling pathway. (PMID:35894142)
  • Gastric cancer metastasis-related NT5DC2 indicates unfavorable prognosis of patients. (PMID:37800836)
  • NT5DC2 knockdown suppresses progression, glycolysis, and neuropathic pain in triple-negative breast cancer by blocking the EGFR pathway. (PMID:38289126)

Cross-species orthologs

5 orthologs

OrganismSymbolGene ID
mus_musculusNt5dc2ENSMUSG00000071547
rattus_norvegicusNt5dc2ENSRNOG00000018358
drosophila_melanogasterNt5cFBGN0033426
drosophila_melanogasterNt5bFBGN0052549
caenorhabditis_elegansWBGENE00022201

Paralogs (4): NT5C2 (ENSG00000076685), NT5DC3 (ENSG00000111696), NT5DC4 (ENSG00000144130), NT5DC1 (ENSG00000178425)

Protein

Protein identifiers

5’-nucleotidase domain-containing protein 2 — Q9H857 (reviewed: Q9H857)

All UniProt accessions (5): C9J036, Q9H857, F8WEY1, H7C4G8, H7C519

UniProt curated annotations — full annotation on UniProt →

Function. Promotes dephosphorylation of tyrosine 3-monooxygenase TH which decreases TH catalytic activity and leads to reduced synthesis of catecholamines including dopamine, noradrenaline and adrenaline. The exact mechanism of activity is unknown but may act as a phosphatase or promote the activity of phosphatases or may inhibit phosphorylation by acting as a barrier to interfere with protein kinase access.

Subunit / interactions. Interacts with tyrosine 3-monooxygenase TH; the interaction results in reduced phosphorylation and decreased catalytic activity of TH.

Subcellular location. Cytoplasm.

Similarity. Belongs to the 5’(3’)-deoxyribonucleotidase family.

Isoforms (4)

UniProt IDNamesCanonical?
Q9H857-11yes
Q9H857-22
Q9H857-33
Q9H857-44

RefSeq proteins (2): NP_001127703, NP_075059 (=MANE)

Domains & families (InterPro)

IDNameType
IPR008380HAD-SF_hydro_IG_5-nuclFamily
IPR016695Pur_nucleotidaseFamily
IPR023214HAD_sfHomologous_superfamily
IPR036412HAD-like_sfHomologous_superfamily

Pfam: PF05761

UniProt features (13 total): sequence conflict 3, binding site 3, splice variant 3, active site 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q9H857-F186.690.75

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 73 (nucleophile); 75 (proton donor)

Ligand- & substrate-binding residues (3): 73; 75; 358

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 161 (showing top): RNGTGGGC_UNKNOWN, GOBP_PHENOL_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_PHENOL_CONTAINING_COMPOUND_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_PEPTIDYL_SERINE_MODIFICATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_REGULATION_OF_OXIDOREDUCTASE_ACTIVITY, GOBP_REGULATION_OF_AMINE_METABOLIC_PROCESS, GOBP_REGULATION_OF_PEPTIDYL_SERINE_PHOSPHORYLATION, GOBP_DOPAMINE_METABOLIC_PROCESS, LE_EGR2_TARGETS_UP, GOBP_NEGATIVE_REGULATION_OF_OXIDOREDUCTASE_ACTIVITY, HEN1_01, GOBP_NEGATIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION

GO Biological Process (4): negative regulation of peptidyl-serine phosphorylation (GO:0033137), obsolete negative regulation of catecholamine metabolic process (GO:0045914), negative regulation of oxidoreductase activity (GO:0051354), negative regulation of dopamine biosynthetic process (GO:1903180)

GO Molecular Function (3): 5’-nucleotidase activity (GO:0008253), metal ion binding (GO:0046872), hydrolase activity (GO:0016787)

GO Cellular Component (2): cytoplasm (GO:0005737), mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
negative regulation of protein phosphorylation1
peptidyl-serine phosphorylation1
regulation of peptidyl-serine phosphorylation1
oxidoreductase activity1
negative regulation of catalytic activity1
regulation of oxidoreductase activity1
negative regulation of biosynthetic process1
dopamine biosynthetic process1
negative regulation of dopamine metabolic process1
regulation of dopamine biosynthetic process1
nucleotidase activity1
cation binding1
catalytic activity1
intracellular anatomical structure1
cellular anatomical structure1
cytoplasm1
intracellular membrane-bounded organelle1

Protein interactions and networks

STRING

776 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
NT5DC2UQCC5Q8WVI0511
NT5DC2STIMATEQ86TL2510
NT5DC2CENPWQ5EE01470
NT5DC2PPM1MQ96MI6463
NT5DC2LRATD1Q96KN4462
NT5DC2ZNF664Q8N3J9448
NT5DC2THP07101443
NT5DC2UBE2TQ9NPD8443
NT5DC2C2orf69Q8N8R5436
NT5DC2PLPP6Q8IY26430
NT5DC2CCDC92Q53HC0428
NT5DC2PUDPQ08623424
NT5DC2CST9LQ9H4G1423
NT5DC2MTMR9Q96QG7394
NT5DC2BCO2Q9BYV7387

IntAct

65 interactions, top by confidence:

ABTypeScore
CFTRESYT2psi-mi:“MI:2364”(proximity)0.710
ETFRF1NDUFAB1psi-mi:“MI:0914”(association)0.640
EMILIN1METTL15psi-mi:“MI:0914”(association)0.530
KCTD17CBX4psi-mi:“MI:0914”(association)0.530
TOLLIPIRAK2psi-mi:“MI:0914”(association)0.500
NT5DC3NT5DC2psi-mi:“MI:0915”(physical association)0.400
HSPB2NT5DC2psi-mi:“MI:0915”(physical association)0.370
NT5DC2TSG101psi-mi:“MI:0915”(physical association)0.370
SIRT4VWA8psi-mi:“MI:0914”(association)0.350
TSNAXpsi-mi:“MI:0914”(association)0.350
HIF1ANCNOT1psi-mi:“MI:0914”(association)0.350
HSCBRBP5psi-mi:“MI:0914”(association)0.350
CUL3PXDNLpsi-mi:“MI:0914”(association)0.350
LRRK2psi-mi:“MI:0914”(association)0.350
FMC1NDUFAB1psi-mi:“MI:0914”(association)0.350
CISD3POLRMTpsi-mi:“MI:0914”(association)0.350
XPNPEP3COQ9psi-mi:“MI:0914”(association)0.350
FMC1DNM1Lpsi-mi:“MI:0914”(association)0.350
COQ9ACOT7psi-mi:“MI:0914”(association)0.350
XPNPEP3ALDH1L1psi-mi:“MI:0914”(association)0.350
FMC1POLRMTpsi-mi:“MI:0914”(association)0.350

BioGRID (134): NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Two-hybrid), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS), NT5DC2 (Affinity Capture-MS)

ESM2 similar proteins: A0A3L7I2I8, A6H7H7, D4ABP9, O60733, O95476, P37287, P97570, P97819, Q12980, Q1RMV9, Q20432, Q28EX9, Q28HW9, Q29I63, Q2KIX2, Q2KJD7, Q2TBU5, Q3B7T6, Q3TP92, Q3U1V6, Q3UHB1, Q4R678, Q5F480, Q5FWT7, Q5R4C4, Q5TFE4, Q5U395, Q5U3T3, Q5ZJJ8, Q61C05, Q66H63, Q6NWD4, Q6NYU2, Q80YV4, Q86UY8, Q8AYC9, Q8BGR9, Q8BM85, Q8JIL9, Q8VIJ8

Diamond homologs: A4IHT9, Q3UHB1, Q54XC1, Q5TFE4, Q6GN91, Q6Q0N3, Q75K12, Q86UY8, Q86YG4, Q9H857, Q2TBU5, Q5EBF1, Q5ZIZ4, Q6DKB0, Q8C5P5, D3ZMY7, O46411, P49902, Q3V1L4, Q5RA22

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

124 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance91
Likely benign2
Benign0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2150 predictions. Top by Δscore:

VariantEffectΔscore
3:52524812:CTCA:Cdonor_loss1.0000
3:52524813:TCA:Tdonor_loss1.0000
3:52524816:C:CTdonor_loss1.0000
3:52524877:TAGGT:Tacceptor_gain1.0000
3:52524878:AGGT:Aacceptor_gain1.0000
3:52524879:GGT:Gacceptor_gain1.0000
3:52524880:GT:Gacceptor_gain1.0000
3:52524882:C:Aacceptor_loss1.0000
3:52524882:C:CCacceptor_gain1.0000
3:52524959:ACAC:Adonor_loss1.0000
3:52524960:CACC:Cdonor_loss1.0000
3:52524961:AC:Adonor_loss1.0000
3:52524965:G:Adonor_gain1.0000
3:52525019:A:ACdonor_gain1.0000
3:52525020:C:CCdonor_gain1.0000
3:52525102:TC:Tacceptor_gain1.0000
3:52525102:TCC:Tacceptor_loss1.0000
3:52525103:CC:Cacceptor_gain1.0000
3:52525104:C:CCacceptor_gain1.0000
3:52525104:CT:Cacceptor_loss1.0000
3:52525105:T:Aacceptor_loss1.0000
3:52525202:C:Adonor_gain1.0000
3:52525292:TTCCC:Tacceptor_loss1.0000
3:52525293:TCCCT:Tacceptor_loss1.0000
3:52525294:CC:Cacceptor_gain1.0000
3:52525295:CC:Cacceptor_gain1.0000
3:52525297:T:Aacceptor_loss1.0000
3:52527288:CCTTA:Cdonor_loss1.0000
3:52527289:CTTA:Cdonor_loss1.0000
3:52527290:TTA:Tdonor_loss1.0000

AlphaMissense

3672 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
3:52524684:C:GR450P1.000
3:52524696:C:AG446V1.000
3:52525069:G:TA377D1.000
3:52525072:C:TG376D1.000
3:52525082:A:GW373R1.000
3:52525082:A:TW373R1.000
3:52525213:A:GL364P1.000
3:52525215:A:CD363E1.000
3:52525215:A:TD363E1.000
3:52525216:T:AD363V1.000
3:52525216:T:CD363G1.000
3:52525216:T:GD363A1.000
3:52525217:C:GD363H1.000
3:52525231:T:AD358V1.000
3:52525231:T:CD358G1.000
3:52525231:T:GD358A1.000
3:52525234:C:AG357V1.000
3:52525234:C:TG357E1.000
3:52525235:C:AG357W1.000
3:52525235:C:GG357R1.000
3:52525235:C:TG357R1.000
3:52525294:C:TG337E1.000
3:52527631:G:CF304L1.000
3:52527631:G:TF304L1.000
3:52527633:A:GF304L1.000
3:52527634:G:CF303L1.000
3:52527634:G:TF303L1.000
3:52527636:A:GF303L1.000
3:52527643:C:AK300N1.000
3:52527643:C:GK300N1.000

dbSNP variants (sampled 300 via entrez): RS1000039280 (3:52536808 A>G), RS1000449787 (3:52531698 G>A), RS1000810387 (3:52525412 G>A), RS1000859453 (3:52527112 C>T), RS1001051732 (3:52533104 C>A,T), RS1001092868 (3:52526388 C>T), RS1001197086 (3:52531100 C>T), RS1001219838 (3:52533304 CGCCCCCGGGCGTCGGGGCGCCCCAGAG>C), RS1001258857 (3:52525935 A>G), RS1001379772 (3:52533284 C>G,T), RS1001384085 (3:52532211 C>CTTAGAA), RS1001385100 (3:52531761 C>A,G), RS1002038278 (3:52526738 C>T), RS1002219413 (3:52532739 G>A), RS1002908351 (3:52527082 T>C)

Disease associations

OMIM: gene MIM:621077 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

35 associations (top):

StudyTraitp-value
GCST001241_15Bipolar disorder2.000000e-06
GCST002149_14Schizophrenia1.000000e-08
GCST002539_48Schizophrenia4.000000e-11
GCST002774_8Cognitive function5.000000e-06
GCST002782_110Waist-to-hip ratio adjusted for body mass index3.000000e-10
GCST002782_111Waist-to-hip ratio adjusted for body mass index7.000000e-11
GCST002782_262Waist-to-hip ratio adjusted for body mass index1.000000e-09
GCST002782_263Waist-to-hip ratio adjusted for body mass index3.000000e-10
GCST004063_106Waist circumference adjusted for body mass index6.000000e-10
GCST004063_169Waist circumference adjusted for body mass index1.000000e-08
GCST004500_50Waist circumference adjusted for BMI (adjusted for smoking behaviour)7.000000e-07
GCST004500_95Waist circumference adjusted for BMI (adjusted for smoking behaviour)4.000000e-07
GCST004501_119Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)3.000000e-07
GCST004501_120Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)1.000000e-06
GCST004505_89Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)2.000000e-06
GCST004521_123Autism spectrum disorder or schizophrenia3.000000e-12
GCST004521_201Autism spectrum disorder or schizophrenia4.000000e-08
GCST004521_259Autism spectrum disorder or schizophrenia6.000000e-09
GCST004615_10Hemoglobin concentration6.000000e-09
GCST004622_161Reticulocyte count2.000000e-15
GCST005316_131Intelligence (MTAG)8.000000e-11
GCST006269_1074General cognitive ability2.000000e-11
GCST006269_512General cognitive ability3.000000e-15
GCST006803_55Schizophrenia1.000000e-11
GCST008103_3Bipolar disorder7.000000e-11
GCST010083_130Hemoglobin levels2.000000e-14
GCST010698_14Subcortical volume (min-P)8.000000e-09
GCST010699_73Brain morphology (min-P)1.000000e-18
GCST010701_137Cortical surface area (MOSTest)8.000000e-10
GCST010702_70Subcortical volume (MOSTest)2.000000e-11

EFO canonical traits (8, from GWAS)

EFO IDTrait name
EFO:0004337intelligence
EFO:0007788BMI-adjusted waist-hip ratio
EFO:0007789BMI-adjusted waist circumference
EFO:0004318smoking behavior
EFO:0004509hemoglobin measurement
EFO:0007986reticulocyte count
EFO:0004346neuroimaging measurement
EFO:0004348hematocrit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295945 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
5.76Kd1724nMCHEMBL5653589
5.76ED501724nMCHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 3 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide2148892: Binding affinity to human NT5DC2 incubated for 45 mins by Kinobead based pull down assaykd1.7236uM

CTD chemical–gene interactions

62 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
sodium arseniteincreases abundance, increases expression, affects methylation, decreases expression5
methylmercuric chlorideincreases expression, affects cotreatment2
Air Pollutantsdecreases expression, increases abundance, increases expression2
Estradiolaffects cotreatment, increases expression2
Phenylmercuric Acetateaffects cotreatment, decreases expression2
Smokedecreases expression, increases abundance, increases expression2
Valproic Acidincreases expression, increases methylation2
Particulate Matterdecreases expression, increases abundance, increases expression2
bisphenol Fincreases expression1
bisphenol Aaffects expression1
methylparabenincreases expression1
sodium bichromatedecreases expression1
mono-(2-ethylhexyl)phthalatedecreases methylation, increases abundance1
tris(1,3-dichloro-2-propyl)phosphatedecreases expression1
cobaltous chloridedecreases expression1
potassium chromate(VI)decreases expression1
ferrous chloridedecreases expression1
perfluorooctane sulfonic acidincreases expression1
pentabromodiphenyl etherdecreases expression1
CGP 52608affects binding, increases reaction1
K 7174decreases expression1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideaffects cotreatment, increases expression, decreases expression1
erucylphospho-N,N,N-trimethylpropylammoniumdecreases expression1
ICG 001increases expression1
abrinedecreases expression1
2,2’,4,4’-tetrabromodiphenyl etherdecreases expression1
dorsomorphinaffects cotreatment, increases expression, decreases expression1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidinedecreases expression, increases response to substance1
NSC 689534decreases expression, affects binding1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic aciddecreases expression1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL4232645BindingBinding affinity to NT5DC2 cysteine residue in human 786-O cell soluble proteomic lysate at 5 uM incubated for 1 hr followed by cell lysis by IA-alkyne probe based isoTOP-ABPP analysisCovalent inhibitors of nicotinamide N-methyltransferase (NNMT) provide evidence for target engagement challenges in situ. — Bioorg Med Chem Lett

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

CellosaurusNameCategorySex
CVCL_TB24HAP1 NT5DC2 (-) 1Cancer cell lineMale
CVCL_XR20HAP1 NT5DC2 (-) 2Cancer cell lineMale
CVCL_XR21HAP1 NT5DC2 (-) 3Cancer cell lineMale
CVCL_XR22HAP1 NT5DC2 (-) 4Cancer cell lineMale

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 77

This page pulls from 77 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomerefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot